Preparation of New Doxorubicin Hydrochloride Liposomes  

作　　者：Zhixia WANG 

机构地区：[1]School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai,Shandong 264005,China

出　　处：《Medicinal Plant》2024年第6期1-6,共6页药用植物（英文）

摘　　要：[Objectives]To prepare protopanaxadiol type doxorubicin hydrochloride liposomes by replacing cholesterol with protopanaxadiol,a derivative of ginsenoside,which has a similar structure with cholesterol,to reduce the adverse reaction of adriamycin(doxorubicin)and improve the shortcomings of ordinary doxorubicin hydrochloride.[Methods]Liposomes were prepared by thin film dispersion-ammonium sulfate gradient method,and the optimal formulation was screened by Box-Behnken experiment with particle size and encapsulation efficiency as the evaluation indicator through single factor experiment,and the drug release in vitro was verified.[Results]The average particle size of the liposomes was(149.21±1.2)nm,the polydispersity index(PDI)was(0.22±0.02),and the potential was-(15.22±1.57)mV.The liposomes were spherical and uniform in size;the encapsulation efficiency and drug loading of the new doxorubicin hydrochloride liposomes were(89.71±4.4)%and(7.28±0.8)%,respectively.[Conclusions]The new doxorubicin hydrochloride liposomes was successfully prepared by a film dispersion-ammonium sulfate gradient method,the internal circulation of the doxorubicin hydrochloride liposomes was prolonged,and the new material has good stability.This study is expected to lay a foundation for the successful preparation of new doxorubicin hydrochloride liposomes in vitro and in vivo.

关 键 词：TUMOR Doxorubicin hydrochloride liposomes Targeted therapy PROTOPANAXADIOL Clinical requirement 

分 类 号：R285[医药卫生—中药学]